Menu

United Therapeutics Corporation UTHR

Full chart Compare
Set alert

Price alert · UTHR

All alert types
591.23 USD +2.62 (+0.44%)

Nov 11, 2026, 10:52 AM EST

583.80 Day range 593.95
452.44 52-week range 614.23
YTD
+21.34%
1 year
+28.75%
Market cap
25.18B
Revenue (ttm)
3.19B
Profit margin
38.61%
EPS (ttm)
26.49
Shares out
42.59M
P/E ratio
22.32
Forward P/E
16.59
YTD return
+21.34%
1-year return
+28.75%
Volume
51.74K
Avg volume
703.88K
Open
588.36
Previous close
588.61
Day's range
583.80 – 593.95
52-week range
452.44 – 614.23
Beta
0.48
Analysts
Buy
Price target
687.14 (+16.2%)
Earnings date
Feb 24, 2027

5D -6.64 (-1.11%)

560580600ThuFriMonTueWed592.49

Key statistics

Enterprise value
22.74B
PEG ratio
2.22
Price / sales
7.86
Price / book
3.97
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
4.10%
Free cash flow
454.62M
Total cash
2.07B
Total debt
0
Return on equity
19.13%
Short % of float
6.79%
50-day average
535.33
200-day average
535.04

Financials — quick view

All financials
UTHR Revenue — quarterly 832.50M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
UTHR Net income — quarterly 258.60M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
UTHR EPS — quarterly 6.06
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

UTHR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20265.88———
Nov 4, 2026Sep 30, 20266.015.71-0.30-4.99%
Aug 5, 2026Jun 30, 20266.867.27+0.41+5.98%
May 6, 2026Mar 31, 20267.005.82-1.18-16.86%
Feb 25, 2026Dec 31, 20257.137.70+0.57+7.99%
Oct 29, 2025Sep 30, 20256.897.16+0.27+3.92%

Upgrades / downgrades

UTHR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026TD CowenmainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026Wells FargomainOverweightOverweight
Nov 4, 2026BTIGmainBuyBuy
Oct 28, 2026JP MorganmainOverweightOverweight
Oct 22, 2026RBC CapitalmainOutperformOutperform

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
unither.com

News

Your note

Sign in to keep a note on UTHR — it syncs with the Stock Master app.

Insider holders

UTHR insider holders
InsiderRelationLatest transactionDateShares held
BENKOWITZ MICHAELPresidentConversion of Exercise of derivative securityMar 12, 20260
CAUSEY CHRISTOPHERDirectorSaleMar 29, 20264,190
EDGEMOND JAMES C.Chief Financial OfficerSaleJun 21, 202618,876
GILTNER RICHARD ADirectorConversion of Exercise of derivative securityJul 8, 202621,884
KURZWEIL RAYMOND CDirectorConversion of Exercise of derivative securityJul 8, 202613,320
MAHON PAUL AGeneral CounselSaleNov 4, 202645,172

Institution ownership

UTHR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.43%5,294,5293.12BJun 29, 2026
Avoro Capital Advisors LLC6.52%2,777,7771.64BJun 29, 2026
Vanguard Portfolio Management LLC4.51%1,919,4291.13BJun 29, 2026
Vanguard Capital Management LLC4.50%1,918,2561.13BJun 29, 2026
State Street Corporation4.46%1,898,0641.12BJun 29, 2026
Renaissance Technologies, LLC4.01%1,708,7391.01BJun 29, 2026

Fund ownership

UTHR fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.59%1,527,799899.28MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%1,347,720793.28MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%973,490573.01MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.69%719,385423.44MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%486,555286.39MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.76%323,432190.38MSep 29, 2026